Efficacy and Safety of Catheter Ablation vs. Antiarrhythmic Drugs For Ventricular Tachycardia (VANISH2) – American College of Cardiology
Catheter ablation as a first-line strategy for ventricular tachycardia (VT) in patients with ischemic cardiomyopathy reduces the composite endpoint of death or serious arrhythmia outcomes compared with antiarrhythmic drugs (AADs). Catheter ablation was associated with fewer treated sustained VTs below the detection rate versus AADs. How does the efficacy and safety of catheter ablation as first-line therapy compare with antiarrhythmic drug (AAD) therapy for ventricular tachycardia (VT) in patients with
